| Literature DB >> 29959968 |
Guillermo León1, Mariángela Vargas2, Álvaro Segura2, María Herrera2, Mauren Villalta2, Andrés Sánchez2, Gabriela Solano2, Aarón Gómez2, Melvin Sánchez2, Ricardo Estrada2, José María Gutiérrez2.
Abstract
Snake antivenoms are formulations of animal immunoglobulins used in the treatment of snakebite envenomation. The general scheme for producing snake antivenoms has undergone few changes since its development more than a century ago; however, technological innovations have been introduced in the manufacturing process. These medicines must comply with identity, purity, safety and efficacy profiles, as requested by the current Good Manufacturing Practices (GMPs) applied to modern biopharmaceutical drugs. Industrial production of snake antivenoms comprises several stages, such as: 1) production of reference venom pools, 2) production of hyperimmune plasma, 3) purification of the antivenom immunoglobulins, 4) formulation of the antivenom, 5) stabilization of the formulation, and 6) quality control of in-process and final products. In this work, a general review of the existing technology used for the industrial manufacture of snake antivenoms is presented.Keywords: Antivenom; Envenomation; Industrial biotechnology; Snake; Venoms
Mesh:
Substances:
Year: 2018 PMID: 29959968 DOI: 10.1016/j.toxicon.2018.06.084
Source DB: PubMed Journal: Toxicon ISSN: 0041-0101 Impact factor: 3.033